Accordingly, PTX3 overexpression can inhibit FGF-driven epithelial-to-mesenchymal transition (EMT) and tumor/metastatic burden in melanoma models [13] and hampers tumor growth in preclinical models of prostate cancer and fibrosarcoma [8,10]. This evidence concerns the gene PTX3 and neoplasm.